Last reviewed · How we verify
BCMA-CS1 cCAR T cells
iCell Gene Therapeutics' BCMA-CS1 cCAR T cells are in early clinical development for relapsed/refractory multiple myeloma. The therapy targets BCMA and CS1 antigens, aiming to enhance efficacy and reduce resistance. Early Phase 1 trials are ongoing with promising preliminary results.
At a glance
| Generic name | BCMA-CS1 cCAR T cells |
|---|---|
| Sponsor | iCell Gene Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCMA-CS1 cCAR T cells CI brief — competitive landscape report
- BCMA-CS1 cCAR T cells updates RSS · CI watch RSS
- iCell Gene Therapeutics portfolio CI